Influencer Jeff Tang flagged the change and blamed Eli Lilly. Videos stay up, but slight misspellings still get past the keyword block.
Recap by typeshit. Full story at SecNews.gr.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
The FDA rated the recall Class II and reports no illnesses. The North Carolina compounder got an FDA warning letter in December 2025. Lot numbers are listed at the source.
A brief post notes growing concern over reports of serious eye problems in people taking Ozempic and similar drugs, while research into the link continues.
Loading…